BioSpace News Archive

Peer-reviewed study challenges existing quality control standards to outline future safety and potency benchmarks

BioArctic AB announces that new data related to BAN2401 were presented on July 17.

Inflection Biosciences, a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences, a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.

Senseonics Holdings, Inc. announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Two new companies join the GDN, expanding this novel worldwide network of leading diagnostics service providers with nine members spanning the globe, the GDN has a presence in countries covering two-thirds of the world’s population, and over 90% of the global pharmaceutical market

The Leapfrog Group, an independent national health care watchdog organization, released Safety In Numbers: The Leapfrog Group’s Report on High-Risk Surgeries Performed at American Hospitals.

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, introduces a new chip device that offers superior identification of miniscule blood residues for forensic applications.

Kronos is Focused on the Development of Therapies for Targets Traditionally Viewed as ‘Undruggable’

ViewRay, Inc. announced details relating to the release of its second quarter 2019 financial results.

Kersia, the global leader in food safety, announces the acquisition of Choisy Laboratories, a leading developer and manufacturer of chemical, biotechnological and biosecurity hygiene solutions based in Canada, from the Trudeau family and Champlain Financial Corporation.